- Telehealth Visits
- Insurance plan information
Mehrdad Matloubian, MD, PhD
Rheumatology- Telehealth Visits
- Insurance plan information
Mehrdad Matloubian, MD, PhD
Rheumatology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Mehrdad Matloubian is a rheumatologist who specializes in treating inflammatory and autoimmune diseases.
In research, Matloubian has a special interest in the role of lymphocyte trafficking – the movement process of certain white blood cells toward an inflamed area – in autoimmune diseases, such as rheumatoid arthritis.
Matloubian earned his medical degree from the David Geffen School of Medicine at UCLA. He completed his residency in internal medicine and a fellowship in rheumatology at UCSF.
Education & training
Board certification
- Rheumatology, American Board of Internal Medicine/Rheumatology
Fellowship
- Rheumatology, UCSF Graduate Medical Education
Residency
- Internal Medicine, UCSF Graduate Medical Education
Internship
- Internal Medicine, UCSF Graduate Medical Education
Degree
- MD, University of California Los Angeles
My expertise
Specialties
Locations
My research
Publications
Showing 1-6 of 43 reviews
- February 5, 20264 out of 5 Stars
Good
- January 31, 20265 out of 5 Stars
Dr Matloubian is amazing
- January 9, 20264.9 out of 5 Stars
My physician (Dr. Matloubian) is excellent, he takes time to listen to my concerns n explains our next step clearly.
- January 6, 20265 out of 5 Stars
Wonderful encounter, compassionate, caring, efficient, knowledgeable, humorous - unusually really nice doctor. 5 stars
- December 14, 20255 out of 5 Stars
I have recommended Dr Matloubian to several friends. He truly cares.
- December 7, 20255 out of 5 Stars
Dr. M is an excellent doctor. He listens and explains carefully. He is honest about what he doesn't know.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.